Dry Eye Assessment and Management (DREAM©) Study: Study design and baseline characteristics.

ABSTRACT:

Purpose

Describe trial design and baseline characteristics of participants in the DRy Eye Assessment and Management (DREAM©) Study.

Design

Prospective, multi-center, randomized, double-masked "real-world" clinical trial assessing efficacy and safety of oral omega-3 (ω3) supplementation for the treatment of dry eye disease (DED).

Methods

RESULTS: Mean age of participants was 58.0 ± 13.2 years. Mean OSDI score at baseline was 44.4 ± 14.2. Mean conjunctival staining score (scale 0-6) was 3.0 ± 1.4, corneal staining score (scale 0-15) was 3.9 ± 2.7, tear break-up time was 3.1 ± 1.5 s, and Schirmer test was 9.6 ± 6.5 mm/5 min.

Conclusions

DREAM© participants mirror real world patients who seek intervention for their DED-related symptoms despite their current treatme

SUBMITTER: Asbell PA 

PROVIDER: S-EPMC7250048 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature